GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping closer to potentially changing lives of patients living with
ViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination cutting the number of drugs taken to suppress the disease from three to two, f
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
